CD274 and non-small cell lung carcinoma: Therefore, here we conducted a network meta-analysis (NMA) according to three PD-L1 expression level subgroups (<1%, 1–49%, and ≥50%) to evaluate the pooled effect of checkpoint inhibitors and assess the relative efficacy among the three checkpoint inhibitors in advanced NSCLC patients.